Log in

Progenics Pharmaceuticals News Headlines (NASDAQ:PGNX)

$3.59
-0.26 (-6.75 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$3.48
Now: $3.59
$3.80
50-Day Range
$2.11
MA: $4.11
$5.16
52-Week Range
$1.89
Now: $3.59
$6.37
Volume677,868 shs
Average Volume1.42 million shs
Market Capitalization$310.89 million
P/E RatioN/A
Dividend YieldN/A
Beta2.31

Headlines

Progenics Pharmaceuticals (NASDAQ PGNX) News Headlines

Source:
DateHeadline
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Given Consensus Recommendation of "Hold" by BrokeragesProgenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 19 at 3:54 AM
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Short Interest Down 10.1% in FebruaryProgenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Short Interest Down 10.1% in February
www.americanbankingnews.com - March 14 at 3:20 PM
Progenics Pharmaceuticals (NASDAQ:PGNX) Posts Quarterly  Earnings Results, Beats Estimates By $0.12 EPSProgenics Pharmaceuticals (NASDAQ:PGNX) Posts Quarterly Earnings Results, Beats Estimates By $0.12 EPS
www.americanbankingnews.com - March 14 at 11:18 AM
Progenics Pharmaceuticals EPS beats by $0.12, beats on revenueProgenics Pharmaceuticals EPS beats by $0.12, beats on revenue
seekingalpha.com - March 13 at 1:11 PM
PROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTSPROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS
finance.yahoo.com - March 13 at 1:10 PM
Merger Arbitrage Mondays: Morgan Stanley Acquires E*Trade Financial CorporationMerger Arbitrage Mondays: Morgan Stanley Acquires E*Trade Financial Corporation
seekingalpha.com - February 25 at 6:56 PM
Progenics up 11% on improved merger terms with LantheusProgenics up 11% on improved merger terms with Lantheus
seekingalpha.com - February 20 at 4:20 PM
Lantheus and Progenics Agree to Amended Transaction TermsLantheus and Progenics Agree to Amended Transaction Terms
www.businesswire.com - February 20 at 11:42 AM
Progenics Pharmaceuticals Announces Presentations at the 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium Annual Meeting (ASCO GU)Progenics Pharmaceuticals Announces Presentations at the 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium Annual Meeting (ASCO GU)
finance.yahoo.com - February 6 at 9:00 AM
BRIEF-Progenics Pharmaceuticals Provides Update On Reconstituted Boards Ongoing Strategic ReviewBRIEF-Progenics Pharmaceuticals Provides Update On Reconstituted Board's Ongoing Strategic Review
www.msn.com - January 21 at 9:48 PM
Progenics Pharmaceuticals Provides Update on Reconstituted Boards Ongoing Strategic ReviewProgenics Pharmaceuticals Provides Update on Reconstituted Board's Ongoing Strategic Review
www.marketwatch.com - January 21 at 9:48 PM
Progenics Pharmaceuticals Provides Update on Reconstituted Board’s Ongoing Strategic ReviewProgenics Pharmaceuticals Provides Update on Reconstituted Board’s Ongoing Strategic Review
finance.yahoo.com - January 21 at 4:48 PM
Progenics Pharmaceuticals Announces Presentation at the 2020 SNMMI Mid-Winter MeetingProgenics Pharmaceuticals Announces Presentation at the 2020 SNMMI Mid-Winter Meeting
finance.yahoo.com - January 16 at 1:06 PM
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Progenics Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmIMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Progenics Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - January 14 at 5:32 PM
INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Progenics Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmINVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Progenics Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - January 11 at 2:16 AM
ONGOING SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Progenics Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmONGOING SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Progenics Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - January 9 at 3:44 AM
IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Progenics Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmIMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Progenics Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - January 7 at 6:00 PM
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Progenics Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmINVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Progenics Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
www.businesswire.com - January 6 at 6:13 PM
BRIEF-Progenics Pharma Announces Phase 3 CONDOR Trial Of PyL In Prostate Cancer Achieved Primary EndpointBRIEF-Progenics Pharma Announces Phase 3 CONDOR Trial Of PyL In Prostate Cancer Achieved Primary Endpoint
www.msn.com - December 23 at 10:36 PM
ACST On Watch, ITCI Jumps 250% On Trial Data, CVM Slumps, FDA Nod For AGN ACST On Watch, ITCI Jumps 250% On Trial Data, CVM Slumps, FDA Nod For AGN
www.rttnews.com - December 23 at 10:17 PM
Progenics +20% premarket on positive PyL data in prostate cancerProgenics +20% premarket on positive PyL data in prostate cancer
seekingalpha.com - December 23 at 12:33 PM
Progenics Pharmaceuticals stock soars 29% on news of positive results in prostate cancer drug trialProgenics Pharmaceuticals stock soars 29% on news of positive results in prostate cancer drug trial
finance.yahoo.com - December 23 at 12:33 PM
Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL(TM) in Prostate Cancer Achieved Primary EndpointProgenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL(TM) in Prostate Cancer Achieved Primary Endpoint
www.marketwatch.com - December 23 at 7:32 AM
Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL™ in Prostate Cancer Achieved Primary EndpointProgenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL™ in Prostate Cancer Achieved Primary Endpoint
finance.yahoo.com - December 23 at 7:32 AM
Progenics Pharmaceuticals to Announce and Host a Conference Call to Discuss Top Line Results from Phase 3 CONDOR Trial of PyL™ in Prostate Cancer on Monday, December 23rdProgenics Pharmaceuticals to Announce and Host a Conference Call to Discuss Top Line Results from Phase 3 CONDOR Trial of PyL™ in Prostate Cancer on Monday, December 23rd
www.benzinga.com - December 22 at 6:17 PM
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Progenics Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Progenics Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
www.businesswire.com - December 20 at 4:00 PM
Here is What Hedge Funds Think About Progenics Pharmaceuticals, Inc. (PGNX)Here is What Hedge Funds Think About Progenics Pharmaceuticals, Inc. (PGNX)
finance.yahoo.com - December 13 at 7:45 PM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation Regarding the November 12, 2019 Registration Statement of Progenics Pharmaceuticals, Inc.SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation Regarding the November 12, 2019 Registration Statement of Progenics Pharmaceuticals, Inc.
www.prnewswire.com - December 11 at 6:34 PM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – AXE, CISN, IPHS, PGNXSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – AXE, CISN, IPHS, PGNX
finance.yahoo.com - December 10 at 12:37 PM
SHAREHOLDER ALERT: Monteverde & Associates PC Reminds Investors of its Ongoing Investigation Regarding the MergerSHAREHOLDER ALERT: Monteverde & Associates PC Reminds Investors of its Ongoing Investigation Regarding the Merger
finance.yahoo.com - December 6 at 6:19 PM
INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – AMTD, TIF, MDCO, PGNXINVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – AMTD, TIF, MDCO, PGNX
finance.yahoo.com - December 4 at 8:14 AM
Progenics Pharmaceuticals Announces Presentations at the Radiological Society of North America (RSNA) Annual MeetingProgenics Pharmaceuticals Announces Presentations at the Radiological Society of North America (RSNA) Annual Meeting
finance.yahoo.com - November 25 at 3:09 PM
Progenics Pharma taps Mims as interim CEOProgenics Pharma taps Mims as interim CEO
seekingalpha.com - November 22 at 6:52 AM
Progenics Pharmaceuticals Appoints David Mims as Interim Chief Executive OfficerProgenics Pharmaceuticals Appoints David Mims as Interim Chief Executive Officer
finance.yahoo.com - November 21 at 6:58 PM
Velan Receives Requisite Number of Written Consents to Reconstitute Majority of Progenics BoardVelan Receives Requisite Number of Written Consents to Reconstitute Majority of Progenics Board
finance.yahoo.com - November 8 at 5:34 PM
Progenics Pharmaceuticals Announces Delivery of Consents and Revocations to Independent Inspector of ElectionsProgenics Pharmaceuticals Announces Delivery of Consents and Revocations to Independent Inspector of Elections
finance.yahoo.com - November 8 at 5:34 PM
BRIEF-Progenics Pharmaceuticals Says Q3 Revenue Of $5.6 Million Versus $5.3 MillionBRIEF-Progenics Pharmaceuticals Says Q3 Revenue Of $5.6 Million Versus $5.3 Million
www.msn.com - November 7 at 7:31 PM
Analysts Estimate Progenics (PGNX) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate Progenics (PGNX) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - November 7 at 2:30 PM
Progenics (PGNX) Reports Q3 Loss, Lags Revenue EstimatesProgenics (PGNX) Reports Q3 Loss, Lags Revenue Estimates
finance.yahoo.com - November 7 at 2:30 PM
Progenics Pharmaceuticals EPS beats by $0.04, misses on revenueProgenics Pharmaceuticals EPS beats by $0.04, misses on revenue
seekingalpha.com - November 7 at 9:29 AM
Progenics Reminds Shareholders that November 17 is the True Deadline for Velan’s Consent SolicitationProgenics Reminds Shareholders that November 17 is the True Deadline for Velan’s Consent Solicitation
finance.yahoo.com - November 6 at 12:35 PM
Glass Lewis Recommends Stockholders Vote on GREEN Consent Card for Velan Nominees to Constitute Majority of Progenics BoardGlass Lewis Recommends Stockholders Vote on GREEN Consent Card for Velan Nominees to Constitute Majority of Progenics Board
finance.yahoo.com - November 4 at 12:15 PM
Progenics Urges Shareholders to Reject the Risk and Uncertainty That Would be Caused by Giving Velan’s Nominees Control of the BoardProgenics Urges Shareholders to Reject the Risk and Uncertainty That Would be Caused by Giving Velan’s Nominees Control of the Board
finance.yahoo.com - November 4 at 12:15 PM
Progenics Reminds Shareholders that November 17 is the Only Deadline for Velans Consent SolicitationProgenics Reminds Shareholders that November 17 is the Only Deadline for Velan's Consent Solicitation
www.marketwatch.com - November 1 at 7:35 PM
Progenics Reminds Shareholders that November 17 is the Only Deadline for Velan’s Consent SolicitationProgenics Reminds Shareholders that November 17 is the Only Deadline for Velan’s Consent Solicitation
finance.yahoo.com - November 1 at 2:35 PM
Progenics Pharmaceuticals, Inc. (PGNX) Is Burning These Hedge FundsProgenics Pharmaceuticals, Inc. (PGNX) Is Burning These Hedge Funds
finance.yahoo.com - October 31 at 12:18 AM
ISS Recommends Shareholders Vote on the GREEN Consent Card for Election of Velan Nominees and Removal of Progenics CEOISS Recommends Shareholders Vote on the GREEN Consent Card for Election of Velan Nominees and Removal of Progenics CEO
finance.yahoo.com - October 28 at 8:22 AM
Independent Director Candidates Nominated by Velan Issue Letter to Progenics ShareholdersIndependent Director Candidates Nominated by Velan Issue Letter to Progenics Shareholders
finance.yahoo.com - October 24 at 6:31 PM
Velan Responds to Misleading Communications from ProgenicsVelan Responds to Misleading Communications from Progenics
finance.yahoo.com - October 23 at 6:03 PM
Progenics To Be Acquired By Lantheus Holdings: Deciding To Buy, Sell, Or HoldProgenics To Be Acquired By Lantheus Holdings: Deciding To Buy, Sell, Or Hold
seekingalpha.com - October 22 at 11:30 PM
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel